Dolutegravir/Lamivudine is a combination of two medications used as a first-line treatment for adults who are new to antiretroviral therapy. This combination helps to reduce the amount of HIV in the blood, which is known as viral suppression. It is taken orally once a day.

Cabotegravir is a long-acting medication used in combination with another drug to maintain viral suppression in people with HIV. It is given as an injection every two months after the initial treatment phase with oral medications.

Rilpivirine is another long-acting medication that is used together with cabotegravir to help keep the HIV virus suppressed in the body. Like cabotegravir, it is administered as an injection every two months.

HIV-1 Infection – HIV-1 infection is a chronic viral condition caused by the human immunodeficiency virus type 1, which attacks the immune system, specifically targeting CD4+ T cells. As the virus replicates, it gradually weakens the immune system, making the body more susceptible to infections and certain cancers. The progression of the disease can vary, but without intervention, it can lead to acquired immunodeficiency syndrome (AIDS), where the immune system is severely compromised. During the early stages, individuals may experience flu-like symptoms, but as the infection progresses, symptoms may become more severe and persistent. The virus is primarily transmitted through unprotected sexual contact, sharing needles, or from mother to child during childbirth or breastfeeding. Regular monitoring of viral load and CD4+ cell count is crucial in managing the disease and preventing progression.